Related Experiment Video
Updated: Jul 3, 2025

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
Published on: January 20, 2023
Qingfei Tongluo Mixture Attenuates Bleomycin-Induced Pulmonary Inflammation and Fibrosis through mTOR-Dependent
Shuyu Ge1, Zhenghong Guo2, Ting Xiao3
1Department of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.
Abstract:
As an interstitial fibrosis disease characterized by diffuse alveolitis and structural alveolar disorders, idiopathic pulmonary fibrosis (IPF) has high lethality but lacks limited therapeutic drugs. A hospital preparation used for the treatment of viral pneumonia, Qingfei Tongluo mixture (QFTL), is rumored to have protective effects against inflammatory and respiratory disease. This study aims to confirm whether it has a therapeutic effect on bleomycin-induced IPF in rats and to elucidate its mechanism of action. Male SD rats were randomly divided into the following groups: control, model, CQ + QFTL (84 mg/kg chloroquine (CQ) + 3.64 g/kg QFTL), QFTL-L, M, H (3.64, 7.28, and 14.56 g/kg, respectively) and pirfenidone (PFD 420 mg/kg). After induction modeling and drug intervention, blood samples and lung tissue were collected for further detection. Body weight and lung coefficient were examined, combined with hematoxylin and eosin (H&E) and Masson staining to observe lung tissue lesions. The enzyme-linked immunosorbent assay (ELISA) and the hydroxyproline (HYP) assay kit were used to detect changes in proinflammatory factors (transforming growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β)) and HYP. Immunohistochemistry and Western blotting were performed to observe changes in proteins related to pulmonary fibrosis (α-smooth muscle actin (α-SMA) and matrix metalloproteinase 12 (MMP12)) and autophagy (P62 and mechanistic target of rapamycin (mTOR)). Treatment with QFTL significantly improved the adverse effects of bleomycin on body weight, lung coefficient, and pathological changes. Then, QFTL reduced bleomycin-induced increases in proinflammatory mediators and HYP. The expression changes of pulmonary fibrosis and autophagy marker proteins are attenuated by QFTL. Furthermore, the autophagy inhibitor CQ significantly reversed the downward trend in HYP levels and α-SMA protein expression, which QFTL improved in BLM-induced pulmonary fibrosis rats. In conclusion, QFTL could effectively attenuate bleomycin-induced inflammation and pulmonary fibrosis through mTOR-dependent autophagy in rats. Therefore, QFTL has the potential to be an alternative treatment for IPF in clinical practice.
Insights
Qingfei Tongluo mixture (QFTL) effectively treats lung fibrosis in rats by reducing inflammation and fibrosis markers. This traditional Chinese medicine shows potential as a new therapy for idiopathic pulmonary fibrosis (IPF).
Area of Science:
- Pulmonology
- Pharmacology
- Cell Biology
Background:
- Idiopathic pulmonary fibrosis (IPF) is a severe lung disease with limited treatment options.
- Qingfei Tongluo mixture (QFTL), used for viral pneumonia, may offer protective effects against respiratory diseases.
- This study investigates QFTL's therapeutic potential for bleomycin-induced IPF in rats.
Purpose of the Study:
- To evaluate the efficacy of QFTL in a rat model of bleomycin-induced pulmonary fibrosis.
- To elucidate the underlying mechanism of QFTL's action, focusing on inflammation and autophagy pathways.
Main Methods:
- Male SD rats were induced with bleomycin and treated with varying doses of QFTL, chloroquine (CQ), or pirfenidone (PFD).
- Lung tissues and blood samples were analyzed for pathological changes, inflammatory mediators (TGF-β, TNF-α, IL-1β), hydroxyproline (HYP) levels, and protein expression (α-SMA, MMP12, P62, mTOR).
- Histological, ELISA, hydroxyproline assay, immunohistochemistry, and Western blotting techniques were employed.
Main Results:
- QFTL treatment significantly improved body weight, lung coefficient, and reduced pathological lung damage in bleomycin-induced rats.
- QFTL administration decreased levels of pro-inflammatory mediators and hydroxyproline, indicating reduced inflammation and fibrosis.
- QFTL attenuated the expression of pulmonary fibrosis markers (α-SMA, MMP12) and modulated autophagy proteins (P62, mTOR).
- The autophagy inhibitor CQ reversed QFTL's beneficial effects on HYP and α-SMA, suggesting QFTL acts via mTOR-dependent autophagy.
Conclusions:
- Qingfei Tongluo mixture (QFTL) demonstrates significant anti-inflammatory and anti-fibrotic effects in a rat model of pulmonary fibrosis.
- The therapeutic mechanism involves the modulation of mTOR-dependent autophagy.
- QFTL holds promise as a potential alternative therapeutic agent for idiopathic pulmonary fibrosis (IPF).
More Related Videos
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018
06:03Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025